Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM0TWCY)

Drug Name

PF-04950615 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Hypercholesterolaemia	5C80.0	Phase 3	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	TTBRG7E	PCSK9_HUMAN	Not Available	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Hypercholesterolaemia

ICD Disease Classification

5C80.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Proprotein convertase subtilisin/kexin type 9 (PCSK9)	DTT	PCSK9	4.82E-02	-0.07	-0.3

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	ClinicalTrials.gov (NCT01975376) The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects. U.S. National Institutes of Health.
2	Phase 3 data for PCSK9 inhibitor wows. Nat Biotechnol. 2013 Dec;31(12):1057-8.